ELABS Fundamental Analysis - ELLIPTIC LABORATORIES ASA

Fundamental Rating

Overall ELABS gets a fundamental rating of 4 out of 10. We evaluated ELABS against 114 industry peers in the Software industry. ELABS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ELABS is growing strongly while it is still valued neutral. This is a good combination!

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ELABS has reported negative net income.

In the past year ELABS has reported a negative cash flow from operations.

ELABS had negative earnings in 4 of the past 5 years.

ELABS had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -3.99%, ELABS is not doing good in the industry: 65.79% of the companies in the same industry are doing better.

ELABS has a Return On Equity of -4.38%. This is comparable to the rest of the industry: ELABS outperforms 40.35% of its industry peers.

		Industry Rank	Sector Rank
ROA	-3.99%
ROE	-4.38%
ROIC	N/A

ROA(3y)-5.97%

ROA(5y)-5.33%

ROE(3y)-6.62%

ROE(5y)-5.96%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ELABS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ELABS does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ELABS has more shares outstanding

Compared to 5 years ago, ELABS has more shares outstanding

ELABS has a better debt/assets ratio than last year.

2.2 Solvency

A Debt/Equity ratio of 0.03 indicates that ELABS is not too dependend on debt financing.

ELABS's Debt to Equity ratio of 0.03 is amongst the best of the industry. ELABS outperforms 83.33% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Altman-Z	N/A

ROIC/WACCN/A

WACC8.83%

2.3 Liquidity

ELABS has a Current Ratio of 7.85. This indicates that ELABS is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 7.85, ELABS belongs to the top of the industry, outperforming 94.74% of the companies in the same industry.

ELABS has a Quick Ratio of 7.85. This indicates that ELABS is financially healthy and has no problem in meeting its short term obligations.

ELABS has a Quick ratio of 7.85. This is amongst the best in the industry. ELABS outperforms 94.74% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.85
Quick Ratio	7.85

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ELABS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.67%, which is quite impressive.

The Revenue has grown by 93.08% in the past year. This is a very strong growth!

The Revenue has been growing by 28.29% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)66.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%175%

Revenue 1Y (TTM)93.08%

Revenue growth 3Y34.19%

Revenue growth 5Y28.29%

Sales Q2Q%49.72%

3.2 Future

The Earnings Per Share is expected to grow by 132.01% on average over the next years. This is a very strong growth

Based on estimates for the next years, ELABS will show a very strong growth in Revenue. The Revenue will grow by 37.98% on average per year.

EPS Next Y15.87%

EPS Next 2Y168.51%

EPS Next 3Y132.01%

EPS Next 5YN/A

Revenue Next Year33.33%

Revenue Next 2Y37.15%

Revenue Next 3Y37.98%

Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ELABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

ELABS is valuated correctly with a Price/Forward Earnings ratio of 12.07.

88.60% of the companies in the same industry are more expensive than ELABS, based on the Price/Forward Earnings ratio.

Compared to an average S&P500 Price/Forward Earnings ratio of 36.12, ELABS is valued rather cheaply.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	12.07

4.2 Price Multiples

ELABS's Enterprise Value to EBITDA ratio is in line with the industry average.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	38.35

4.3 Compensation for Growth

ELABS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

ELABS's earnings are expected to grow with 132.01% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y168.51%

EPS Next 3Y132.01%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ELABS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ELLIPTIC LABORATORIES ASA

OSL:ELABS (11/28/2025, 9:25:18 AM)

6.96

-0.09 (-1.28%)

Chartmill FA Rating

GICS SectorInformation Technology

GICS IndustryGroupSoftware & Services

GICS IndustrySoftware

Earnings (Last)11-20 2025-11-20/bmo

Earnings (Next)N/A N/A

Inst Owners35.3%

Inst Owner ChangeN/A

Ins Owners8.59%

Ins Owner ChangeN/A

Market Cap732.82M

Revenue(TTM)131.91M

Net Income(TTM)-13.42M

Analysts84.44

Price Target19.38 (178.45%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-27.98%

Min Revenue beat(2)-45.84%

Max Revenue beat(2)-10.11%

Revenue beat(4)1

Avg Revenue beat(4)-13.8%

Min Revenue beat(4)-45.84%

Max Revenue beat(4)13.5%

Revenue beat(8)2

Avg Revenue beat(8)-19.97%

Revenue beat(12)2

Avg Revenue beat(12)-22.35%

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)8.11%

EPS NY rev (1m)-10%

EPS NY rev (3m)-83.33%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)4.91%

Revenue NY rev (1m)-0.59%

Revenue NY rev (3m)-20.98%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	12.07
P/S	5.77
P/FCF	N/A
P/OCF	N/A
P/B	2.4
P/tB	3.12
EV/EBITDA	38.35

EPS(TTM)-0.07

EYN/A

EPS(NY)0.58

Fwd EY8.29%

FCF(TTM)-0.3

FCFYN/A

OCF(TTM)-0.01

OCFYN/A

SpS1.21

BVpS2.91

TBVpS2.23

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-3.99%
ROE	-4.38%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-5.97%

ROA(5y)-5.33%

ROE(3y)-6.62%

ROE(5y)-5.96%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.38

Health

		Industry Rank	Sector Rank
Debt/Equity	0.03
Debt/FCF	N/A
Debt/EBITDA	0.52
Cap/Depr	129.41%
Cap/Sales	23.76%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	7.85
Quick Ratio	7.85
Altman-Z	N/A

F-Score6

WACC8.83%

ROIC/WACCN/A

Cap/Depr(3y)167.84%

Cap/Depr(5y)198.62%

Cap/Sales(3y)35.14%

Cap/Sales(5y)37.53%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)66.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%175%

EPS Next Y15.87%

EPS Next 2Y168.51%

EPS Next 3Y132.01%

EPS Next 5YN/A

Revenue 1Y (TTM)93.08%

Revenue growth 3Y34.19%

Revenue growth 5Y28.29%

Sales Q2Q%49.72%

Revenue Next Year33.33%

Revenue Next 2Y37.15%

Revenue Next 3Y37.98%

Revenue Next 5YN/A

EBIT growth 1Y83.37%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year7528.57%

EBIT Next 3Y529.24%

EBIT Next 5YN/A

FCF growth 1Y57.85%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y97.11%

OCF growth 3YN/A

OCF growth 5YN/A

ELLIPTIC LABORATORIES ASA / ELABS.OL FAQ

What is the fundamental rating for ELABS stock?

ChartMill assigns a fundamental rating of 4 / 10 to ELABS.OL.

What is the valuation status for ELABS stock?

ChartMill assigns a valuation rating of 4 / 10 to ELLIPTIC LABORATORIES ASA (ELABS.OL). This can be considered as Fairly Valued.

What is the profitability of ELABS stock?

ELLIPTIC LABORATORIES ASA (ELABS.OL) has a profitability rating of 0 / 10.

What is the financial health of ELLIPTIC LABORATORIES ASA (ELABS.OL) stock?

The financial health rating of ELLIPTIC LABORATORIES ASA (ELABS.OL) is 5 / 10.

Can you provide the expected EPS growth for ELABS stock?

The Earnings per Share (EPS) of ELLIPTIC LABORATORIES ASA (ELABS.OL) is expected to grow by 15.87% in the next year.

ELLIPTIC LABORATORIES ASA (ELABS.OL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ELLIPTIC LABORATORIES ASA / ELABS.OL FAQ

What is the fundamental rating for ELABS stock?

What is the valuation status for ELABS stock?

What is the profitability of ELABS stock?

What is the financial health of ELLIPTIC LABORATORIES ASA (ELABS.OL) stock?

Can you provide the expected EPS growth for ELABS stock?